My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 8 485 / DOI: 10.3332/ecancer.2014.485

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project

Loading Article Metrics ... Please wait

Related articles

Policy: Phosphoethanolamine and the danger of unproven drugs

Abstract | Full Article | PDF | Portuguese Published: 17 Oct 2016 / DOI: 10.3332/ecancer.2016.681

Clinical Study: Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Abstract | Full Article | PDF Published: 12 Oct 2016 / DOI: 10.3332/ecancer.2016.680

Case Report: The first case of benign multicystic mesothelioma presenting as a splenic mass

Abstract | Full Article | PDF Published: 04 Oct 2016 / DOI: 10.3332/ecancer.2016.678

Research: VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions

Abstract | Full Article | PDF Published: 29 Sep 2016 / DOI: 10.3332/ecancer.2016.677

Clinical Study: Is blue dye still required during sentinel lymph node biopsy for breast cancer?

Abstract | Full Article | PDF Published: 19 Sep 2016 / DOI: 10.3332/ecancer.2016.674

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence